Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: Disclosed herein are methods and compositions for performing assays for determining efficacy of drugs using rat SCID models that exhibit excellent take rates, and excellent tumor growth rates. The methods and compositions offer dramatically improved efficiencies compared to corresponding mouse equivalents.

Abstract: The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.

Abstract: The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: Disclosed are non-human mammals having a modified liver and methods of making such non-human mammals having a modified liver. The modified liver may be characterized by a non-germline, stable integration of a non-endogenous gene targeted to the liver of the non-human mammal. In certain aspects, the modified liver may have greater than at least 30% ablation of the endogenous hepatocyte population of the non-human mammal. In certain aspects, the non-human mammal may comprise at least 30% non-endogenous hepatocytes. The disclosed non-human mammals may be useful for pharmacology, drug absorption, distribution, metabolism, and excretion studies, collectively ADME and toxicology studies (ADME-tox), and/or drug screening.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allodynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use.

Abstract: The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine.

Abstract: The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Abstract: Device-based activity classification using predictive feature analysis is described, including evaluating an indicator associated with a predictive feature, identifying an application, using the name, to be performed, and invoking the application, the application being configured to interpret the indicator to determine an operation to perform at one or more levels of a protocol stack using data generated from evaluating a signal detected by a sensor, the sensor being coupled to a wearable device, and the application being configured to perform the operation using other data generated from evaluating another signal detected by another sensor, the another sensor being substantially different than the sensor.

Abstract: Device-based activity classification using predictive feature analysis is described, including receiving a signal from a sensor coupled to a device, the sensor being configured to detect the signal over a time period and to detect motion, evaluating the signal to generate data, the data being used to indicate motion, the data being further evaluated to select a classifier based on whether the motion is detected, activating another sensor coupled to the device, the another sensor being configured to detect another signal that is substantially different than the signal, the another signal being used to generate other data associated with whether the motion is detected, invoking the classifier, the classifier being configured to evaluate a predictive feature to identify a type associated with whether the motion is detected, the predictive feature invoking an application configured to determine the type and a state using a feature interpreter, and processing the data using the application and the feature interpre

Abstract: Device-based activity classification using predictive feature analysis is described, including receiving a signal from a sensor coupled to a device, the sensor being configured to sense the signal over a time period, evaluating the signal to generate data, the data being further evaluated to select a classifier, invoking the classifier, the classifier being configured to evaluate a predictive feature, the predictive feature invoking an application configured to determine a state using a feature interpreter, and processing the data using the application and the feature interpreter to generate information associated with a biological state, the information being configured to display on an interface associated with the device.

Abstract: Device-based activity classification using predictive feature analysis is described, including receiving a signal from a sensor configured to measure a heart rate coupled to a device, the sensor being configured to sense the signal over a time period, evaluating the signal to generate data associated with the heart rate, the data being further evaluated to select a classifier, invoking the classifier, the classifier being configured to evaluate the data to identify a predictive feature, the predictive feature invoking an application configured to determine a state using a feature interpreter, the application also being configured to evaluate other data from another signal, the signal being configured to detect a respiration rate, and processing the data and the other data using the application and the feature interpreter to generate information associated with sleep, the information being configured to display on an interface associated with the device.

Abstract: Techniques for dynamic computation of distance of travel on wearable devices are described. Disclosed are techniques for receiving motion data over context windows from one or more sensors coupled to a wearable device, determining a number of motion units of each context window, determining a motion unit length of each context window as a function of the number of motion units of each context window and a duration of each context window, determining a distance of travel of each context window, and determining a total distance of travel over all context windows. The motion unit length of each context window is variable from the motion unit length of another context window. In some embodiments, the total distance of travel is presented on an interface coupled to the wearable device.

Abstract: Techniques for dynamic computation of distance of travel on wearable devices are described. Disclosed are techniques for determining a number of motion units over a distance for one or more samples, determining a motion unit length of each sample, and creating a model determining a motion unit length as a function of a number of motion units and a duration of the motion units. Further disclosed are techniques for receiving motion data of a user from one or more sensors coupled to the wearable device, accessing the model to determine a motion unit length of the user, and determining a distance of travel of the user, and initiating execution of an operation of the wearable device based on the distance of travel of the user. In one embodiment, the model may be adjusted or calibrated. In another embodiment, the determination of the distance of travel may be verified or corrected.